

TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.



	<b>Dr. Vinay Chopra</b> MD (Pathology & Microbiology) Chairman & Consultant Pathologist		Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist	
NAME	: Mrs. SALMA			
AGE/ GENDER	: 34 YRS/FEMALE		PATIENT ID	: 1792526
COLLECTED BY	:		REG. NO./LAB NO.	: 012503150056
REFERRED BY	:		<b>REGISTRATION DATE</b>	: 15/Mar/2025 04:47 PM
BARCODE NO.	: 01527145		COLLECTION DATE	: 15/Mar/2025 04:50PM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		REPORTING DATE	: 15/Mar/2025 09:05PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD	), AMBALA CANTT		
Test Name		Value	Unit	<b>Biological Reference interval</b>
	CI INI	CAT CHEMIS	TRY/BIOCHEMIST	<b>'DV</b>
	CLINI		DFILE : BASIC	R1
CHOLESTEROL TO	TAL · SFRUM	118.62	mg/dL	OPTIMAL: < 200.0
by CHOLESTEROL OX		110.02	ing/ uL	BORDERLINE HIGH: 200.0 -
				239.0 HIGH CHOLESTEROL: > OR =
				240.0
TRIGLYCERIDES: SERUM by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC)		108.16	mg/dL	OPTIMAL: < 150.0
				BORDERLINE HIGH: 150.0 - 199.0
				HIGH: 200.0 - 499.0
			( ),	VERY HIGH: $> OR = 500.0$
HDL CHOLESTEROL (DIRECT): SERUM by SELECTIVE INHIBITION		41.04	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0
				60.0
		55.95	mg/dI	HIGH HDL: > OR = 60.0 OPTIMAL: < 100.0
LDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY		55.95	mg/dL	ABOVE OPTIMAL: < 100.0 - 129.0
				BORDERLINE HIGH: 130.0 -
				159.0 HIGH: 160.0 - 189.0
				VERY HIGH: > OR = 190.0
NON HDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY		77.58	mg/dL	OPTIMAL: < 130.0
by CALCOLATED, SPE	CIROPHOIOMEIRI			ABOVE OPTIMAL: 130.0 - 159.0 BORDERLINE HIGH: 160.0 -
				189.0
				HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0
VLDL CHOLESTER	DL: SERUM	21.63	mg/dL	0.00 - 45.00
by CALCULATED, SPE	CTROPHOTOMETRY			
TOTAL LIPIDS: SERUM by CALCULATED, SPECTROPHOTOMETRY		345.4 <sup>L</sup>	mg/dL	350.00 - 700.00
CHOLESTEROL/HE		2.89	RATIO	LOW RISK: 3.30 - 4.40
by CALCULATED, SPE	CIKOPHUIOMEIRY			AVERAGE RISK: 4.50 - 7.0
	2	l	1	

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

67

257

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: Ilnd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana 0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com







	Dr. Vinay ChopraDr. Yugam ChopraMD (Pathology & Microbiology)MD (Pathology)Chairman & Consultant PathologistCEO & Consultant Pathologist					
NAME	: Mrs. SALMA					
AGE/ GENDER	: 34 YRS/FEMALE	PAT	IENT ID	: 1792526		
COLLECTED BY	:	REG	. NO./LAB NO.	: 012503150056		
<b>REFERRED BY</b>	:	REG	ISTRATION DATE	: 15/Mar/2025 04:47 PM		
BARCODE NO.	: 01527145	COL	LECTION DATE	: 15/Mar/2025 04:50PM		
CLIENT CODE.	: KOS DIAGNOSTIC LAB	REP	ORTING DATE	: 15/Mar/2025 09:05PM		
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAI	D, AMBALA CANTT				
Test Name		Value	Unit	<b>Biological Reference interval</b>		
LDL/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY		1.36	RATIO	MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0 LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0		
TRIGLYCERIDES/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY		2.64 <sup>L</sup>	RATIO	3.00 - 5.00		

## **INTERPRETATION:**

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for

Total Cholesterol, Triglycerides, HDL & LDL Cholesterol. 2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues. 4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non HDL.

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

End Of Report \*\*\*





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt - 133 001, Haryana 0171-2643898, +91 99910 43898 care@koshealthcare.com www.koshealthcare.com

